EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nanoparticles and Medicine Thirty Years After the First FDA Approval: Time to Renew the Vows

Roberto Molinaro iD, Claudia Corbo iD

Advanced Materials · 2026

DOI: 10.1002/adma.75364 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Materials, 2026. Verfasst von Roberto Molinaro und 1 weiteren Autor:innen. Beteiligte Einrichtung: XGEN Venture SGR S.p.A., Milan, Italy. Hauptthemen laut MEDLINE: Nanoparticles, Nanomedicine, Drug Approval. Die Arbeit nennt 74 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thirty years after the approval of Doxil, nanomedicine has generated extraordinary scientific output and enabled therapeutic modalities that would otherwise have remained impractical. Its clinical translation, however, remains more limited than the scale and sophistication of the field might suggest, particularly when targeted systemic delivery is required. In the recent past, others have highlighted those limitations, however, what concerns us is that some of the assumptions that constrained earlier generations of nanomedicines are now re‐emerging in AAV‐based gene therapy and in vivo CAR‐T platforms. More precise payloads do not make delivery more precise, nor do viral vectors escape the biological barriers encountered by synthetic nanoparticles. In this Perspective, we revisit the liver paradox, the distinction between organ accumulation and functional delivery, the protein corona and the promise of biomimetic systems. Our intention is not to add another catalogue of limitations, but to ask what should change. We argue that the next phase of drug delivery should be less focused on adding complexity to the carrier and more committed to quantifying its biological journey.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesNanomedicineDrug ApprovalHumansAnimalsUnited StatesUnited States Food and Drug AdministrationDrug CarriersDrug Delivery Systems

Stichwörter der Autor:innen

biohybrid nanoparticlesbiological barriersclinical translationnanomedicineprotein coronatargeted drug deliveryviral and nonviral vectors

Substanzen

Drug Carriers

Autor:innen und Institutionen

  • XGEN Venture SGR S.p.A., Milan, Italy.
  • Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.

ORCID-Profile: Roberto Molinaro, Claudia Corbo

Zitieren

APA

Molinaro, R., & Corbo, C. (2026). Nanoparticles and Medicine Thirty Years After the First FDA Approval: Time to Renew the Vows. Advanced Materials. https://doi.org/10.1002/adma.75364

Vancouver

Molinaro R, Corbo C. Nanoparticles and Medicine Thirty Years After the First FDA Approval: Time to Renew the Vows. Advanced Materials. 2026. doi:10.1002/adma.75364

BibTeX
@article{Molinaro2026,
  author = {Molinaro, Roberto and Corbo, Claudia},
  title = {Nanoparticles and Medicine Thirty Years After the First FDA Approval: Time to Renew the Vows},
  journal = {Advanced Materials},
  year = {2026},
  doi = {10.1002/adma.75364}
}
Kostenlos starten →